Published in J Hypertens on July 01, 2009
Chinese Medicine Treat for Hypertensive Renal Injury (CHAIR) | NCT04078711
Epidemic of hypertension in Ghana: a systematic review. BMC Public Health (2010) 1.80
Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J (2013) 1.77
Hypertension awareness, treatment and control in Africa: a systematic review. BMC Cardiovasc Disord (2013) 1.70
2010 Canadian Hypertension Education Program recommendations: An annual update. Can Fam Physician (2010) 1.45
Report of the National Heart, Lung, and Blood Institute Working Group on epigenetics and hypertension. Hypertension (2012) 1.28
Adherence to antihypertensive medications and health outcomes among newly treated hypertensive patients. Clinicoecon Outcomes Res (2011) 1.22
Canadian efforts to prevent and control hypertension. Can J Cardiol (2010) 1.11
Barriers Influencing Linkage to Hypertension Care in Kenya: Qualitative Analysis from the LARK Hypertension Study. J Gen Intern Med (2016) 1.10
Adherence therapy for medication non-compliant patients with hypertension: a randomised controlled trial. J Hum Hypertens (2011) 1.01
Optimizing linkage and retention to hypertension care in rural Kenya (LARK hypertension study): study protocol for a randomized controlled trial. Trials (2014) 0.96
The "rule of halves" does not apply in Peru: awareness, treatment, and control of hypertension and diabetes in rural, urban, and rural-to-urban migrants. Crit Pathw Cardiol (2013) 0.94
Essential hypertension in adolescents and children: Recent advances in causative mechanisms. Indian J Endocrinol Metab (2011) 0.92
Home blood pressure monitoring among Canadian adults with hypertension: results from the 2009 Survey on Living with Chronic Diseases in Canada. Can J Cardiol (2010) 0.90
Telemonitoring-based service redesign for the management of uncontrolled hypertension (HITS): cost and cost-effectiveness analysis of a randomised controlled trial. BMJ Open (2013) 0.89
Time to effectively address hypertension in India. Indian J Med Res (2013) 0.88
Nurse management of hypertension in rural western Kenya: implementation research to optimize delivery. Ann Glob Health (2013) 0.85
Know your blood pressure; the theme of world hypertension day 2014. Iran J Public Health (2014) 0.85
Stroke patients and their attitudes toward mHealth monitoring to support blood pressure control and medication adherence. Mhealth (2016) 0.84
Full coverage for hypertension drugs in rural communities in China. Am J Manag Care (2013) 0.84
Prevalence of risk factors for hypertension: A cross-sectional study in an urban area of Bangladesh. Glob Cardiol Sci Pract (2015) 0.83
Serum lipid profile of newly diagnosed hypertensive patients in nnewi, South-East Nigeria. Int J Hypertens (2012) 0.83
An integrated approach to preventing cardiovascular disease: community-based approaches, health system initiatives, and public health policy. Risk Manag Healthc Policy (2010) 0.83
2011 Canadian Hypertension Education Program recommendations: an annual update. Can Fam Physician (2011) 0.82
Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic. Vasc Health Risk Manag (2012) 0.81
Behaviour change strategies for reducing blood pressure-related disease burden: findings from a global implementation research programme. Implement Sci (2015) 0.81
Prehypertension is not associated with all-cause mortality: a systematic review and meta-analysis of prospective studies. PLoS One (2013) 0.81
Direct costs of hypertensive patients admitted to hospital in Vietnam- a bottom-up micro-costing analysis. BMC Health Serv Res (2014) 0.80
On the occasion of world hypertension day 2014: A nephrology point of view. J Res Med Sci (2014) 0.80
Antihypertensive Effect of the GaMiSamHwangSaSimTang in Spontaneous Hypertensive Rats. Evid Based Complement Alternat Med (2015) 0.79
Hypertension Vaccine may be a boon to millions in developing world. Hum Vaccin Immunother (2013) 0.78
Can Aliskiren be Considered as a New Novel Drug for Hypertension? Cureus (2015) 0.78
Epidemiology of hypertension and chronic kidney disease in China. Curr Opin Nephrol Hypertens (2010) 0.78
High Prevalence of Hypertension in a Danish Population Telemedical Home Measurement of Blood Pressure in Citizens Aged 55-64 Years in Holstebro County. Am J Hypertens (2015) 0.77
Prevalence and Associated Factors of Hypertension: A Community-Based Cross-Sectional Study in Municipalities of Kathmandu, Nepal. Int J Hypertens (2016) 0.77
Improved Blood Pressure Control to Reduce Cardiovascular Disease Morbidity and Mortality: The Standardized Hypertension Treatment and Prevention Project. J Clin Hypertens (Greenwich) (2016) 0.76
Prevalence of Hypertension among Adults in Remote Rural Areas of Xinjiang, China. Int J Environ Res Public Health (2016) 0.76
Development of a Wearable Cardiac Monitoring System for Behavioral Neurocardiac Training: A Usability Study. JMIR Mhealth Uhealth (2016) 0.76
Barriers and Facilitators to Nurse Management of Hypertension: A Qualitative Analysis from Western Kenya. Ethn Dis (2016) 0.75
Hypertension Prevalence, Awareness, Treatment, and Control in Selected LMIC Communities: Results From the NHLBI/UHG Network of Centers of Excellence for Chronic Diseases. Glob Heart (2016) 0.75
Antihypertensive therapy among newly treated patients: An analysis of adherence and cost of treatment over years. Clinicoecon Outcomes Res (2010) 0.75
Increased NBCn1 expression, Na+/HCO3- co-transport and intracellular pH in human vascular smooth muscle cells with a risk allele for hypertension. Hum Mol Genet (2017) 0.75
Hypertension. Glob Adv Health Med (2012) 0.75
Salt Use Behaviours of Ghanaians and South Africans: A Comparative Study of Knowledge, Attitudes and Practices. Nutrients (2017) 0.75
Closing the blood pressure gap: an affordable proposal to save lives worldwide. BMJ Glob Health (2017) 0.75
Global burden of blood-pressure-related disease, 2001. Lancet (2008) 11.09
Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med (2005) 8.49
Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19
The survival benefits of AIDS treatment in the United States. J Infect Dis (2006) 7.08
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med (2006) 5.62
Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med (2006) 5.53
Does preventive care save money? Health economics and the presidential candidates. N Engl J Med (2008) 4.78
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med (2013) 4.43
Tobacco industry strategies for influencing European Community tobacco advertising legislation. Lancet (2002) 4.38
E-cigarettes: a rapidly growing Internet phenomenon. Ann Intern Med (2010) 4.34
When to start antiretroviral therapy in resource-limited settings. Ann Intern Med (2009) 4.31
Medicare and cost-effectiveness analysis. N Engl J Med (2005) 4.20
Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet (2006) 3.60
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med (2014) 3.57
Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis (2009) 3.30
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA (2003) 3.25
Growing epidemic of coronary heart disease in low- and middle-income countries. Curr Probl Cardiol (2010) 3.23
Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst (2004) 3.11
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10
Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol (2002) 3.09
Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96
Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol (2011) 2.83
The future of health information technology in the patient-centered medical home. Health Aff (Millwood) (2010) 2.82
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78
Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med (2005) 2.60
Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med (2003) 2.48
Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis (2005) 2.47
Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis. Med Decis Making (2007) 2.46
Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS (2005) 2.39
Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology (2008) 2.37
Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med (2006) 2.28
Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal. PLoS Med (2009) 2.13
Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis (2009) 1.95
Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making (2002) 1.94
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med (2015) 1.89
Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making (2012) 1.81
Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. Circulation (2005) 1.80
Projected effects of tobacco smoking on worldwide tuberculosis control: mathematical modelling analysis. BMJ (2011) 1.80
Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making (2002) 1.78
Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6. Value Health (2012) 1.76
Cost-effectiveness of HIV testing and treatment in the United States. Clin Infect Dis (2007) 1.70
Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients. Am J Manag Care (2004) 1.69
Legislating against use of cost-effectiveness information. N Engl J Med (2010) 1.68
The cost effectiveness of gonorrhea screening in urban emergency departments. Sex Transm Dis (2005) 1.64
The lifetime medical cost savings from preventing HIV in the United States. Med Care (2015) 1.61
Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr (2010) 1.57
Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis (2007) 1.57
Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Am J Med (2005) 1.56
Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age. AIDS (2015) 1.49
Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. Value Health (2008) 1.48
Medicare Chronic Care Management Payments and Financial Returns to Primary Care Practices: A Modeling Study. Ann Intern Med (2015) 1.44
Outcomes and costs of acute treatment of traumatic brain injury. J Trauma (2002) 1.44
A survey of tobacco dependence treatment guidelines in 121 countries. Addiction (2013) 1.44
The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin Infect Dis (2007) 1.43
Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease. Am J Health Syst Pharm (2012) 1.41
Uncertainty and patient heterogeneity in medical decision models. Med Decis Making (2010) 1.38
Cost-effectiveness of coronary MDCT in the triage of patients with acute chest pain. AJR Am J Roentgenol (2008) 1.37
Comparative effectiveness evidence from the spine patient outcomes research trial: surgical versus nonoperative care for spinal stenosis, degenerative spondylolisthesis, and intervertebral disc herniation. Spine (Phila Pa 1976) (2011) 1.36
Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS (2007) 1.34
Clinical outcomes and cost-effectiveness of coronary computed tomography angiography in the evaluation of patients with chest pain. J Am Coll Cardiol (2009) 1.34
High risk for occupational exposure to HIV and utilization of post-exposure prophylaxis in a teaching hospital in Pune, India. BMC Infect Dis (2008) 1.31
HIV drug resistance surveillance for prioritizing treatment in resource-limited settings. AIDS (2007) 1.30
Economic model of a birth cohort screening program for hepatitis C virus. Hepatology (2012) 1.28
Optimal allocation of testing dollars: the example of HIV counseling, testing, and referral. Med Decis Making (2005) 1.28
Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol (2002) 1.26
Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period. Cancer (2008) 1.26
How much are Americans willing to pay for a quality-adjusted life year? Med Care (2008) 1.26
Economic burden of childhood autism spectrum disorders. Pediatrics (2014) 1.26
Comparative effectiveness: asking the right questions, choosing the right method. Health Aff (Millwood) (2005) 1.25
A comparison of population-based pneumonia surveillance and health-seeking behavior in two provinces in rural Thailand. Int J Infect Dis (2008) 1.25
Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine (2010) 1.23
Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis? Arthritis Rheumatol (2014) 1.21
Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med (2002) 1.21
Population-level changes in folate intake by age, gender, and race/ethnicity after folic acid fortification. Am J Public Health (2006) 1.17
The gap between estimated incidence of end-stage renal disease and use of therapy. PLoS One (2013) 1.16
Identifying key parameters in cost-effectiveness analysis using value of information: a comparison of methods. Health Econ (2006) 1.14
Estimation of mortality rates for disease simulation models using Bayesian evidence synthesis. Med Decis Making (2006) 1.14
When does quality-adjusting life-years matter in cost-effectiveness analysis? Health Econ (2004) 1.14
Projected cost-effectiveness of smoking cessation interventions in patients hospitalized with myocardial infarction. Arch Intern Med (2011) 1.14
Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy. J Acquir Immune Defic Syndr (2002) 1.13
Annual financial impact of well-differentiated thyroid cancer care in the United States. Cancer (2014) 1.13
Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging--Markov Monte Carlo decision analysis. Radiology (2008) 1.13
Measuring the costs of outreach motivational interviewing for smoking cessation and relapse prevention among low-income pregnant women. BMC Pregnancy Childbirth (2009) 1.12
A comparative assessment of non-laboratory-based versus commonly used laboratory-based cardiovascular disease risk scores in the NHANES III population. PLoS One (2011) 1.11
Monitoring of antiretroviral therapy in low-resource settings. Lancet (2008) 1.11
Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines. Arch Intern Med (2002) 1.11
Cost-effectiveness of motivational interviewing for smoking cessation and relapse prevention among low-income pregnant women: a randomized controlled trial. Value Health (2007) 1.09
Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity. AIDS (2008) 1.09
Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. Value Health (2007) 1.06
Quality and equity of primary care with patient-centered medical homes: results from a national survey. Med Care (2013) 1.05
Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening. Risk Anal (2012) 1.05
Comparison of CKD awareness in a screening population using the Modification of Diet in Renal Disease (MDRD) study and CKD Epidemiology Collaboration (CKD-EPI) equations. Am J Kidney Dis (2011) 1.04
Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antivir Ther (2002) 1.04
The effect of tobacco control measures during a period of rising cardiovascular disease risk in India: a mathematical model of myocardial infarction and stroke. PLoS Med (2013) 1.04
High prevalence of type 2 diabetes among the urban middle class in Bangladesh. BMC Public Health (2013) 1.03
A survey of tobacco dependence treatment services in 121 countries. Addiction (2013) 1.03
Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial. AIDS (2012) 1.03
Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health (2004) 1.02